Home > Protocol Summaries: Compounds > GSK233705/GW642444 Protocol Summaries: GSK233705/GW642444 GSKStudy ID Phase Title Status 111581 Phase 2 A multicenter, randomized, double-blind, placebo-controlled, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD Completed DB1111581 phase 2 A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD Completed
